- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04723251
The Gratitude Gallery - A Positive Psychology Intervention
This study will assess the feasibility and acceptability of a positive psychology intervention, The Gratitude Gallery, for increasing gratitude in adults.
The study hypothesizes that participants will find the activity feasible and acceptable and complete the intervention as directed. The project also hypothesizes that those that complete the intervention will show an increase in self-reported gratitude, as well as a decrease in symptoms of anxiety and depression.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48109
- University of Michigan
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Able to read/understand English and give consent
- Owns a smart phone capable of taking pictures
- Willing and able to comply with all aspects of study procedures
- PHQ-9 score greater or equal to 5 but less or equal to 14 with no suicidal ideation
- Generalized anxiety disorder (GAD-7) score greater or equal to 0 but less or equal to 9
- No plan to initiate a new program that could increase positive affect during the study period (e.g., psychotherapy, new exercise regimen, meditation classes)
- If on medication then stable (at least 3 months) on dose or not on medication
Exclusion Criteria:
- Having a psychotic disorder active suicidality or severe depressive or anxiety symptoms
- Other factors that at the discretion of the investigators that would adversely affect study participation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Taking Photographs
Participants will be asked to take photos with their cell phone.
|
Participants will photograph images (using a cell phone) that invoke a feeling of gratitude. At least 1 photograph (at any time of the day) should be taken for a period of three weeks. Once the photo images are captured, the participant should spend a moment looking at the image and reflecting on why they are grateful for the subject of the photograph. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Acceptability of the The Gratitude Gallery
Time Frame: 2 years
|
Number of participants that are eligible for the study compared to the number of patients that are enrolled.
The higher the ratio of participants enrolled the higher acceptability.
|
2 years
|
Feasibility of the The Gratitude Gallery
Time Frame: up to 21 days (days of treatment)
|
Participants that complete 15 of the 21 intervention days will be considered to be feasible.
|
up to 21 days (days of treatment)
|
Changes in the level of reported gratitude as measured by the Gratitude Questionnaire - 6 (GQ-6).
Time Frame: Baseline, up to day 60
|
This is a six question, self-reported survey designed to assess individual differences in the proneness to experience gratitude in daily life.
The GQ-6 uses a 7-point Likert scale with responses that range from "strongly disagree" to "strongly agree".
Questions 3 and 6 are reverse scored.
A higher total score indicated higher levels of gratitude.
|
Baseline, up to day 60
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Changes in positive and negative affect as measured by the Positive and Negative Affect Scale (PANAS) Scale
Time Frame: Baseline, up to day 60
|
The PANAS scale is a 20 item mood scale measuring the two primary dimensions of mood.
Responses on a 5-point Likert Scale range from "very slightly or not at all" to "extremely".
Positive affect and negative affect questions are grouped and scored separately.
The PANAS has been shown to be sensitive to short-term fluctuations in mood in addition to showing stability over a longer (2-month) time period.
|
Baseline, up to day 60
|
Changes in General Life Satisfaction - Fixed Form B from the NIH Toolbox
Time Frame: Baseline, up to day 60
|
This is a brief 5-item questionnaire which can be administered to adults over the age of 18.
It uses a 7-point Likert scale with responses that range from "strongly disagree" to "strongly agree".
The scores for each question are added to create a raw score.
This raw score is then converted to a T-score using a conversion table which represents the mean of the United States population.
|
Baseline, up to day 60
|
Changes in sleep quality using the Patient-Reported Outcomes Measurement Information System (PROMIS) Sleep Disturbance - Short Form 4a
Time Frame: Baseline, up to day 60
|
This assessment consists of 4 items which measure sleep quality and sleep disturbances using a 5 point likert scale ranging in value from 1 to 5 with higher scores indicating greater sleep quality.
|
Baseline, up to day 60
|
Changes in depressive symptoms using the Patient Health Questionnaire 9-Item (PHQ-9)
Time Frame: Baseline, up to day 60
|
The PHQ-9 is a brief, self-administered questionnaire that scores each of the Diagnostic and Statistical Manual of Mental Disorders (DSM) criteria for depression on a scale from 0 to 3. Response options include "not at all", "several days", more than half the days" and "nearly every day".
It is a validated measure of depression severity.
Scores of 5, 10, 15, and 20 represent mild, moderate, moderately severe, and severe depression, respectively.
|
Baseline, up to day 60
|
Changes in anxiety symptoms using the Generalized Anxiety scale (GAD-7)
Time Frame: Baseline, up to day 60
|
The GAD-7 is a self-reported questionnaire that assesses for the seven core symptoms of generalized anxiety disorder and severity.
Response options include "not at all", "several days", more than half the days" and "nearly every day".
GAD-7 total score for the seven items ranges from 0 to 21. Scores of 5, 10, and 15 represent cut-points for mild, moderate, and severe anxiety, respectively.
|
Baseline, up to day 60
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Erin Hendriks, MD, University of Michigan
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- HUM00177310
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
Kintsugi Mindful Wellness, Inc.Sonar Strategies; Vituity PsychiatryRecruitingDepression | Depression Moderate | Depression Severe | Depression MildUnited States
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
-
Lawson Health Research InstituteTerminated
Clinical Trials on taking photographs
-
Children's Hospital of PhiladelphiaCompleted
-
Nantes University HospitalCompletedPatients at Risk for MelanomaFrance
-
Kevin ClearyGeorge Washington University; Children's National Research Institute; Chiang...Recruiting
-
Barnes Retina InstituteCompletedNuclear Sclerotic CataractUnited States
-
Instituto Universitario de Oftalmobiología Aplicada...CompletedOcular Hypertension | Glaucoma | Glaucoma, SuspectSpain
-
Outcome ReaAssistance Publique - Hôpitaux de Paris; University Hospital, Clermont-Ferrand and other collaboratorsRecruitingCatheter InfectionFrance
-
Rehmat Memorial Post Graduate Dental Teaching HospitalCompletedOral Hygiene | PhotographsPakistan